LT2905338T - Transgeninė pelė su modifikuotu endogeniniu lambda imunoglobulino lokusu - Google Patents

Transgeninė pelė su modifikuotu endogeniniu lambda imunoglobulino lokusu

Info

Publication number
LT2905338T
LT2905338T LTEP14198318.9T LT14198318T LT2905338T LT 2905338 T LT2905338 T LT 2905338T LT 14198318 T LT14198318 T LT 14198318T LT 2905338 T LT2905338 T LT 2905338T
Authority
LT
Lithuania
Prior art keywords
immunoglobulin locus
modified endogenous
endogenous lambda
lambda immunoglobulin
trangenic mice
Prior art date
Application number
LTEP14198318.9T
Other languages
English (en)
Inventor
Andrew J. Murphy
Sean Stevens
Cagan Gurer
Lynn Macdonald
Karolina A. Hosiawa
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of LT2905338T publication Critical patent/LT2905338T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
LTEP14198318.9T 2010-06-22 2011-06-22 Transgeninė pelė su modifikuotu endogeniniu lambda imunoglobulino lokusu LT2905338T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35731710P 2010-06-22 2010-06-22
US35731410P 2010-06-22 2010-06-22

Publications (1)

Publication Number Publication Date
LT2905338T true LT2905338T (lt) 2017-12-27

Family

ID=44509861

Family Applications (4)

Application Number Title Priority Date Filing Date
LTEP16154526.4T LT3034608T (lt) 2010-06-22 2011-06-22 Pelės, ekspresuojančios imunoglobulino hibridinę lengvąją grandinę, turinčią žmogaus kintamąją sritį
LTEP12195716.1T LT2568049T (lt) 2010-06-22 2011-06-22 Pelė, ekspresuojanti imunoglobulino hibridinę lengvąją grandinę su žmogaus kintama sritimi
LTEP14198318.9T LT2905338T (lt) 2010-06-22 2011-06-22 Transgeninė pelė su modifikuotu endogeniniu lambda imunoglobulino lokusu
LTEP11728508.0T LT2480675T (lt) 2010-06-22 2011-06-22 Pelė, ekspresuojanti lengvąją grandinę su žmogaus liambda kintama ir pelės pastoviąja sritimis

Family Applications Before (2)

Application Number Title Priority Date Filing Date
LTEP16154526.4T LT3034608T (lt) 2010-06-22 2011-06-22 Pelės, ekspresuojančios imunoglobulino hibridinę lengvąją grandinę, turinčią žmogaus kintamąją sritį
LTEP12195716.1T LT2568049T (lt) 2010-06-22 2011-06-22 Pelė, ekspresuojanti imunoglobulino hibridinę lengvąją grandinę su žmogaus kintama sritimi

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP11728508.0T LT2480675T (lt) 2010-06-22 2011-06-22 Pelė, ekspresuojanti lengvąją grandinę su žmogaus liambda kintama ir pelės pastoviąja sritimis

Country Status (31)

Country Link
US (21) US9035128B2 (lt)
EP (7) EP2568049B1 (lt)
JP (15) JP6009441B2 (lt)
KR (16) KR101945352B1 (lt)
CN (4) CN104404050B (lt)
AU (1) AU2011271046B2 (lt)
BR (3) BR112012032991B1 (lt)
CA (2) CA2803864C (lt)
CY (5) CY1117537T1 (lt)
DK (5) DK2480676T3 (lt)
ES (5) ES2721749T3 (lt)
HK (4) HK1168384A1 (lt)
HR (5) HRP20160497T1 (lt)
HU (5) HUE044001T2 (lt)
IL (11) IL300712A (lt)
LT (4) LT3034608T (lt)
ME (5) ME03386B (lt)
MX (6) MX336344B (lt)
MY (6) MY165287A (lt)
NO (1) NO2905338T3 (lt)
NZ (6) NZ626979A (lt)
PL (5) PL2480676T3 (lt)
PT (5) PT2905338T (lt)
RS (5) RS58736B1 (lt)
RU (3) RU2601297C2 (lt)
SG (4) SG186391A1 (lt)
SI (5) SI2905338T1 (lt)
SM (3) SMT201600212B (lt)
TR (1) TR201905992T4 (lt)
WO (2) WO2011163311A1 (lt)
ZA (5) ZA201300063B (lt)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
KR101826224B1 (ko) * 2008-09-30 2018-02-06 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
CA2747534C (en) 2008-12-18 2020-08-18 Erasmus University Medical Center Rotterdam Non-human transgenic animals expressing humanised antibodies and use therof
DK2564695T3 (en) 2009-07-08 2015-05-26 Kymab Ltd Animal models and therapeutic molecules
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
WO2011097603A1 (en) 2010-02-08 2011-08-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
EP3248462B1 (en) 2010-03-31 2024-03-13 Ablexis, LLC Genetic engineering of mice for the production of chimeric antibodies
CN104404050B (zh) 2010-06-22 2018-06-08 瑞泽恩制药公司 杂交轻链小鼠
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
EP2597945B1 (en) 2010-07-26 2020-07-22 Trianni, Inc. Transgenic animals and methods of use
SG10201912639SA (en) 2010-08-02 2020-02-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
WO2013041845A2 (en) 2011-09-19 2013-03-28 Kymab Limited Animals, repertoires & methods
CN107056936B (zh) 2011-09-19 2021-09-03 科马布有限公司 免疫球蛋白基因多样性的操纵及多抗体治疗剂
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SG10201913164YA (en) 2011-12-20 2020-03-30 Regeneron Pharma Humanized light chain mice
RS57118B1 (sr) 2012-03-16 2018-06-29 Regeneron Pharma Antitela sa lakim lancem konstruisanim sa histidinom i genetički modifikovani glodari za generisanje istih
LT2825037T (lt) 2012-03-16 2019-08-12 Regeneron Pharmaceuticals, Inc. Graužikai, ekspresuojantys ph jautrias imunoglobulino sekas
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
RU2014141536A (ru) 2012-03-16 2016-05-10 Регенерон Фармасьютикалз, Инк. Мыши, которые продуцируют антигенсвязывающие белки с зависимыми от величины ph характеристиками связывания
WO2013144567A1 (en) 2012-03-28 2013-10-03 Kymab Limited Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
JP5993102B2 (ja) 2013-02-20 2016-09-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 修飾された免疫グロブリン重鎖配列を有する非ヒト動物
EP4218409A3 (en) * 2013-03-13 2023-08-30 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
EP2967012B1 (en) 2013-03-14 2020-09-16 Erasmus University Medical Center Rotterdam Transgenic non-human mammal for antibody production
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) * 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
ES2738679T3 (es) * 2013-09-18 2020-01-24 Regeneron Pharma Anticuerpos de cadena ligera diseñados genéticamente con histidina y animales no humanos modificados genéticamente para generar los mismos
EP3051942B1 (en) 2013-10-01 2020-09-02 Kymab Limited Animal models and therapeutic molecules
WO2015103999A1 (en) * 2014-01-10 2015-07-16 Hung Alfur Fu-Hsin Transgenic animals capable of producing humanized ige at much higher levels than mouse ige
JP2017510273A (ja) * 2014-03-21 2017-04-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 異なる結合特性を示すｖｌ抗原結合タンパク質
RU2016141307A (ru) 2014-03-21 2018-04-24 Регенерон Фармасьютикалз, Инк. Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
PE20170441A1 (es) 2014-06-06 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
CA2959428A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
EP3201226A2 (en) 2014-10-03 2017-08-09 Massachusetts Institute of Technology Antibodies that bind ebola glycoprotein and uses thereof
CN113773388A (zh) 2014-11-21 2021-12-10 百时美施贵宝公司 抗cd73抗体及其用途
CN113563468A (zh) 2014-12-19 2021-10-29 雷根尼桑斯公司 结合人c6的抗体及其用途
KR102644115B1 (ko) 2014-12-23 2024-03-05 브리스톨-마이어스 스큅 컴퍼니 Tigit에 대한 항체
US10358944B2 (en) 2015-02-05 2019-07-23 Basf Se Solar power plant comprising a first heat transfer circuit and a second heat transfer circuit
AU2016232715A1 (en) 2015-03-19 2017-09-28 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
HUE061253T2 (hu) 2015-05-29 2023-06-28 Bristol Myers Squibb Co Antitestek OX40 ellen és azok felhasználásai
CN107922500A (zh) 2015-06-29 2018-04-17 洛克菲勒大学 具有增强的激动剂活性的抗cd40抗体
CN105274116B (zh) * 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 一种制备人源化抗体的核酸分子及其应用
KR20180082563A (ko) 2015-11-19 2018-07-18 브리스톨-마이어스 스큅 컴퍼니 글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
WO2017095939A1 (en) 2015-12-03 2017-06-08 Trianni, Inc. Enhanced immunoglobulin diversity
IL260743B2 (en) 2016-02-04 2024-03-01 Trianni Inc Advanced production of antibodies
IL307425A (en) 2016-03-04 2023-12-01 Univ Rockefeller CD40 antibodies with increased agonistic activity
AU2017228470A1 (en) 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
EA039084B1 (ru) 2016-05-09 2021-12-01 Бристол-Майерс Сквибб Компани Антитела к tl1a и их применения
EP3457840B1 (en) 2016-05-20 2024-04-10 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
DK3462853T3 (da) 2016-06-03 2023-04-03 Regeneron Pharma Gnavere, der udtrykker exogen, terminal deoxynukleotidyltransferase
WO2017214089A1 (en) * 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
US10650241B2 (en) * 2016-06-27 2020-05-12 Facebook, Inc. Systems and methods for identifying matching content
CN109757103B (zh) 2016-07-14 2024-01-02 百时美施贵宝公司 针对tim3的抗体及其用途
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
EP3525815A2 (en) 2016-10-13 2019-08-21 Massachusetts Institute of Technology Antibodies that bind zika virus envelope protein and uses thereof
WO2018128691A1 (en) 2016-11-04 2018-07-12 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
JP7430636B2 (ja) 2017-12-05 2024-02-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 操作された免疫グロブリンラムダ軽鎖を有する非ヒト動物及びその使用
US20220089720A1 (en) 2018-01-12 2022-03-24 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
AU2019236865A1 (en) 2018-03-23 2020-10-01 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
AU2019242551A1 (en) 2018-03-24 2020-10-22 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-MHC complexes, methods of making and uses thereof
EP3772926A1 (en) 2018-03-26 2021-02-17 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
JP7269963B2 (ja) * 2018-06-08 2023-05-09 クリスタル バイオサイエンス インコーポレイテッド 同じ軽鎖ｉを有する多様な抗体を産生するためのトランスジェニック動物
HRP20220509T8 (hr) 2018-06-14 2022-07-22 Regeneron Pharmaceuticals, Inc. Ne-humane životinje sposobne za dh-dh preraspodjelu kodirajućim sekvencama teškog lanca imunoglobulina
EP3872506A4 (en) 2018-10-26 2023-01-11 Vehicle Energy Japan Inc. BATTERY MONITORING DEVICE
JP2022509942A (ja) 2018-11-16 2022-01-25 ブリストル－マイヤーズ スクイブ カンパニー 抗ｎｋｇ２ａ抗体およびその使用
WO2020154293A1 (en) 2019-01-22 2020-07-30 Bristol-Myers Squibb Company Antibodies against il-7r alpha subunit and uses thereof
US11464217B2 (en) 2019-02-22 2022-10-11 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
JP2022535418A (ja) 2019-06-05 2022-08-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド カッパ遺伝子座から発現される限られたラムダ軽鎖レパートリーを有する非ヒト動物及びその使用
CN114554841A (zh) * 2019-07-01 2022-05-27 特里安尼公司 转基因哺乳动物及其使用方法
JP2023504172A (ja) 2019-12-02 2023-02-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
JP2023541216A (ja) * 2020-06-25 2023-09-29 ヒューマブ カンパニー リミテッド ヘテロ接合型トランスジェニック動物
CA3187680A1 (en) 2020-09-11 2022-03-17 Yashu Liu Identification and production of antigen-specific antibodies
CN116848254A (zh) 2020-12-16 2023-10-03 瑞泽恩制药公司 表达人源化Fcα受体的小鼠
AU2021409906A1 (en) 2020-12-23 2023-06-15 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
TW202241934A (zh) 2020-12-23 2022-11-01 美商再生元醫藥公司 編碼錨定修飾抗體之核酸及其用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
IE921169A1 (en) 1991-04-10 1992-10-21 Scripps Research Inst Heterodimeric receptor libraries using phagemids
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
IL109168A0 (en) * 1993-04-01 1994-06-24 Univ Columbia A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
KR20080059467A (ko) * 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
GB9823930D0 (en) * 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
RU2262511C2 (ru) * 2000-05-18 2005-10-20 Джапан Тобакко, Инк. Человеческое моноклональное антитело против ailim, костимулирующей молекулы передачи сигнала, и его фармацевтическое применение
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7041870B2 (en) * 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
GB0031284D0 (en) * 2000-12-21 2001-01-31 Ks Biomedix Ltd High affinity antibodies
AU2002309063B8 (en) * 2001-05-11 2008-04-24 Kyowa Kirin Co., Ltd. Artificial human chromosome containing human antibody lambda light chain gene
GB0115256D0 (en) * 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
CA2847885C (en) * 2001-11-30 2022-03-22 Amgen Fremont Inc. Transgenic animals bearing human ig.lambda. light chain genes
US20030217171A1 (en) 2002-05-17 2003-11-20 Von Stuermer Wolfgang R. Self-replicating and self-installing software apparatus
ES2473596T3 (es) * 2003-07-15 2014-07-07 Therapeutic Human Polyclonals, Inc. Loci de inmunoglobulina humanizada
CN1605628A (zh) * 2003-09-03 2005-04-13 中国疾病预防控制中心病毒病预防控制所 Cho细胞生产的人源抗甲肝病毒基因工程抗体
CN101035808B (zh) * 2004-08-05 2012-10-31 健泰科生物技术公司 人源化抗c-met拮抗剂
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
JP4642862B2 (ja) * 2004-12-29 2011-03-02 ユーハン・コーポレイション ヒト腫瘍壊死因子−アルファに特異的なヒト化抗体
EP2003960B1 (en) 2006-03-31 2015-06-10 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
EP2061812A4 (en) * 2006-08-22 2010-06-09 G2 Inflammation Pty Ltd METHOD FOR THE PRODUCTION OF ANTIBODIES
RU2445318C2 (ru) * 2006-10-02 2012-03-20 Ридженерон Фармасьютикалз, Инк. Высокоаффинные антитела человека к рецептору il-4 человека
US7864492B2 (en) 2006-10-31 2011-01-04 Siemens Industry, Inc. Systems and methods for arc fault detection
DE102007045897A1 (de) 2007-09-26 2009-04-09 Carl Zeiss Microimaging Gmbh Verfahren zur mikroskopischen dreidimensionalen Abbildung einer Probe
CA2721231C (en) * 2008-04-14 2015-10-06 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
US20110123527A1 (en) 2008-05-23 2011-05-26 Hiroaki Shizuya Method of generating single vl domain antibodies in transgenic animals
KR101826224B1 (ko) * 2008-09-30 2018-02-06 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
CA2747534C (en) * 2008-12-18 2020-08-18 Erasmus University Medical Center Rotterdam Non-human transgenic animals expressing humanised antibodies and use therof
DK2564695T3 (en) * 2009-07-08 2015-05-26 Kymab Ltd Animal models and therapeutic molecules
WO2011097603A1 (en) * 2010-02-08 2011-08-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse
AU2011266843C9 (en) 2010-06-17 2018-03-01 Kymab Limited Animal models and therapeutic molecules
CN104404050B (zh) * 2010-06-22 2018-06-08 瑞泽恩制药公司 杂交轻链小鼠

Also Published As

Publication number Publication date
SG186391A1 (en) 2013-01-30
BR112012032991A2 (pt) 2015-10-06
CY1118126T1 (el) 2017-06-28
IL269078B (en) 2021-05-31
IL282872B (en) 2022-04-01
DK2905338T3 (da) 2017-11-06
SG10201504568YA (en) 2015-07-30
MX348942B (es) 2017-07-04
CA2803864C (en) 2017-05-16
US9844212B2 (en) 2017-12-19
JP2020128440A (ja) 2020-08-27
AU2011271043A9 (en) 2015-10-01
KR101975884B1 (ko) 2019-05-10
LT3034608T (lt) 2019-05-27
KR101970944B1 (ko) 2019-04-23
CN103068993A (zh) 2013-04-24
IL291301B2 (en) 2023-07-01
KR102118565B1 (ko) 2020-06-03
US20170258059A1 (en) 2017-09-14
RU2601297C2 (ru) 2016-10-27
CN104404050B (zh) 2018-06-08
IL300712A (en) 2023-04-01
KR20200143511A (ko) 2020-12-23
SI2480676T1 (sl) 2016-10-28
NZ605758A (en) 2014-08-29
US9540452B2 (en) 2017-01-10
JP2018201527A (ja) 2018-12-27
RU2724736C2 (ru) 2020-06-25
HUE029692T2 (en) 2017-03-28
JP6243384B2 (ja) 2017-12-06
US20160057979A1 (en) 2016-03-03
KR20190073584A (ko) 2019-06-26
EP2480676B1 (en) 2016-04-06
KR20190014576A (ko) 2019-02-12
RU2016119423A (ru) 2018-11-07
ME02444B (me) 2016-09-20
KR20180135997A (ko) 2018-12-21
MY194456A (en) 2022-11-30
EP2568049B1 (en) 2016-04-13
PT2480676E (pt) 2016-06-09
KR20230036157A (ko) 2023-03-14
NO2905338T3 (lt) 2017-12-30
ZA201404601B (en) 2016-02-24
JP6545773B2 (ja) 2019-07-17
JP6341972B2 (ja) 2018-06-13
PT2480675T (pt) 2016-07-11
US20150351371A1 (en) 2015-12-10
HRP20171666T1 (hr) 2017-12-15
RS55042B1 (sr) 2016-12-30
NZ707198A (en) 2016-04-29
US9399683B2 (en) 2016-07-26
HK1168384A1 (zh) 2012-12-28
US9163092B2 (en) 2015-10-20
JP7236409B2 (ja) 2023-03-09
KR101991234B1 (ko) 2019-06-20
KR102320944B1 (ko) 2021-11-04
SI3034608T1 (sl) 2019-06-28
US9150662B2 (en) 2015-10-06
US9029628B2 (en) 2015-05-12
IL255179B (en) 2018-06-28
HRP20160497T1 (hr) 2016-07-15
ME02442B (me) 2016-09-20
CN103068993B (zh) 2016-01-06
RS56589B1 (sr) 2018-02-28
IL269078A (en) 2019-11-28
IL223720A (en) 2017-05-29
US9206263B2 (en) 2015-12-08
EP2568049A1 (en) 2013-03-13
US20150089680A1 (en) 2015-03-26
US20170107484A1 (en) 2017-04-20
JP5988969B2 (ja) 2016-09-07
HRP20160794T1 (hr) 2016-08-12
IL255179A0 (en) 2017-12-31
NZ605751A (en) 2014-10-31
RU2016119423A3 (lt) 2019-11-19
JP2020062061A (ja) 2020-04-23
HK1226766A1 (zh) 2017-10-06
KR102001430B1 (ko) 2019-07-18
CA2803864A1 (en) 2011-12-29
EP2480676A1 (en) 2012-08-01
BR112012033248A2 (pt) 2017-11-28
ZA201300063B (en) 2014-09-25
DK3034608T3 (da) 2019-05-06
KR20210073609A (ko) 2021-06-18
HUE044001T2 (hu) 2019-09-30
HRP20190807T1 (hr) 2019-08-23
PL2568049T3 (pl) 2017-03-31
JP2021061863A (ja) 2021-04-22
JP2023133554A (ja) 2023-09-22
WO2011163314A1 (en) 2011-12-29
CN103068994B (zh) 2016-01-20
SG186390A1 (en) 2013-01-30
US20130323790A1 (en) 2013-12-05
KR20180135996A (ko) 2018-12-21
EP3205726A1 (en) 2017-08-16
MY195214A (en) 2023-01-11
KR20210134424A (ko) 2021-11-09
KR102266097B1 (ko) 2021-06-18
PT2905338T (pt) 2017-11-10
HRP20160865T1 (hr) 2016-10-07
US20150246977A1 (en) 2015-09-03
JP2017006152A (ja) 2017-01-12
MX2022002117A (es) 2022-03-17
US20190153384A1 (en) 2019-05-23
CA2804311A1 (en) 2011-12-29
KR20220150430A (ko) 2022-11-10
CA2804311C (en) 2017-09-12
PL2480676T3 (pl) 2016-10-31
US9206262B2 (en) 2015-12-08
BR112012032991B1 (pt) 2021-08-10
MX2012015300A (es) 2013-05-01
KR20190142436A (ko) 2019-12-26
PL3034608T3 (pl) 2019-08-30
BR122020013427B1 (pt) 2021-08-03
EP2905338B1 (en) 2017-08-02
EP2905338A1 (en) 2015-08-12
NZ627119A (en) 2015-05-29
JP2018201528A (ja) 2018-12-27
KR20190014578A (ko) 2019-02-12
JP2017012204A (ja) 2017-01-19
SMT201600213B (it) 2016-08-31
AU2011271046A1 (en) 2013-01-31
NZ626979A (en) 2015-05-29
ZA201506598B (en) 2017-03-29
IL282872A (en) 2021-06-30
US20140137275A1 (en) 2014-05-15
JP2019033765A (ja) 2019-03-07
RS58736B1 (sr) 2019-06-28
KR20130121814A (ko) 2013-11-06
LT2568049T (lt) 2016-10-10
KR20190049932A (ko) 2019-05-09
JP6009441B2 (ja) 2016-10-19
IL291301A (en) 2022-05-01
KR101934852B1 (ko) 2019-01-04
HUE029691T2 (en) 2017-03-28
HUE030285T2 (en) 2017-05-29
KR20130027555A (ko) 2013-03-15
SMT201600212B (it) 2016-08-31
MY195217A (en) 2023-01-11
RU2013102595A (ru) 2014-07-27
KR20200064166A (ko) 2020-06-05
AU2011271043B2 (en) 2015-10-01
DK2480676T3 (en) 2016-06-20
AU2011271046B2 (en) 2015-10-01
IL244450A (en) 2017-11-30
EP2480675B1 (en) 2016-04-06
IL259965A (en) 2018-07-31
ZA201300062B (en) 2014-09-25
JP2013531501A (ja) 2013-08-08
PT3034608T (pt) 2019-05-28
SMT201600229B (lt) 2016-08-31
RU2013102596A (ru) 2014-07-27
US9334333B2 (en) 2016-05-10
US9035128B2 (en) 2015-05-19
CY1122877T1 (el) 2021-05-05
EP2480675A1 (en) 2012-08-01
KR102506001B1 (ko) 2023-03-07
KR102059909B1 (ko) 2019-12-27
JP6073441B2 (ja) 2017-02-01
ES2575223T3 (es) 2016-06-27
IL264634B (en) 2019-09-26
US10266803B2 (en) 2019-04-23
US20180064078A1 (en) 2018-03-08
JP2016010415A (ja) 2016-01-21
SI2905338T1 (sl) 2017-12-29
US20120070861A1 (en) 2012-03-22
HK1183321A1 (zh) 2013-12-20
US20150246976A1 (en) 2015-09-03
IL259965B (en) 2019-02-28
CN104342455A (zh) 2015-02-11
JP2016010417A (ja) 2016-01-21
MY157477A (en) 2016-06-15
US20150173331A1 (en) 2015-06-25
CN103068994A (zh) 2013-04-24
IL223719A (en) 2016-10-31
KR102462042B1 (ko) 2022-11-03
SG10201504324UA (en) 2015-07-30
KR102193823B1 (ko) 2020-12-22
CY1117692T1 (el) 2017-05-17
ZA201404600B (en) 2015-09-30
US20150173332A1 (en) 2015-06-25
CN104404050A (zh) 2015-03-11
EP3034608A1 (en) 2016-06-22
US20160060359A1 (en) 2016-03-03
US20120073004A1 (en) 2012-03-22
WO2011163311A1 (en) 2011-12-29
MX347318B (es) 2017-04-21
NZ707200A (en) 2016-04-29
US9394373B2 (en) 2016-07-19
ME02440B (me) 2016-09-20
IL247386A (en) 2017-07-31
CN104342455B (zh) 2017-05-31
RS54891B1 (sr) 2016-10-31
MY195212A (en) 2023-01-11
US20190203171A1 (en) 2019-07-04
ES2646052T3 (es) 2017-12-11
JP2018023403A (ja) 2018-02-15
DK2568049T3 (en) 2016-08-01
US20200239837A1 (en) 2020-07-30
ME03386B (me) 2020-01-20
RS55037B1 (sr) 2016-12-30
ME02902B (me) 2018-04-20
AU2011271043A1 (en) 2013-01-31
JP2013532974A (ja) 2013-08-22
JP2022066449A (ja) 2022-04-28
SI2480675T1 (sl) 2016-08-31
MX336344B (es) 2016-01-15
HK1170766A1 (zh) 2013-03-08
US9006511B2 (en) 2015-04-14
PL2905338T3 (pl) 2018-01-31
IL291301B1 (en) 2023-03-01
US9206261B2 (en) 2015-12-08
MY165287A (en) 2018-03-21
ES2576928T3 (es) 2016-07-12
EP3456832A1 (en) 2019-03-20
PL2480675T3 (pl) 2017-03-31
PT2568049T (pt) 2016-07-11
KR20210013376A (ko) 2021-02-03
BR112012032991A8 (pt) 2020-09-29
EP3034608B1 (en) 2019-01-30
ES2570131T3 (es) 2016-05-17
US9012717B2 (en) 2015-04-21
EP2905338B8 (en) 2018-01-24
IL244450A0 (en) 2016-04-21
HUE036597T2 (hu) 2018-07-30
RU2590594C2 (ru) 2016-07-10
CY1117537T1 (el) 2017-04-26
JP6963542B2 (ja) 2021-11-10
US9850462B2 (en) 2017-12-26
US20130326647A1 (en) 2013-12-05
SI2568049T1 (sl) 2016-10-28
KR101945352B1 (ko) 2019-02-07
TR201905992T4 (tr) 2019-05-21
MX347322B (es) 2017-04-21
MX2012015298A (es) 2013-05-01
CY1119478T1 (el) 2018-03-07
US9226484B2 (en) 2016-01-05
AU2011271043A8 (en) 2016-01-21
US9066502B2 (en) 2015-06-30
DK2480675T3 (en) 2016-08-01
LT2480675T (lt) 2016-10-10
ES2721749T3 (es) 2019-08-05
US20150176002A1 (en) 2015-06-25
US20150320023A1 (en) 2015-11-12
KR102211911B1 (ko) 2021-02-05

Similar Documents

Publication Publication Date Title
LT2905338T (lt) Transgeninė pelė su modifikuotu endogeniniu lambda imunoglobulino lokusu
GB2500496B (en) Lift-gas optimization with choke control
IL224441B (en) Antibodies with modified isoelectric points
ZA201305123B (en) Modified antibody with improved half-life
PT3012268T (pt) Recetores de antigénio quimérico com uma região de charneira otimizada
KR102165560B9 (ko) 핵연료 집합체
EP2425009A4 (en) IMMUNOREACTIVE ENHANCED ANTIBODIES WITH HEREGULINE COUPLE HER3
EP2534229A4 (en) OXYGENATED FUEL
EP2709511A4 (en) CATHETER WITH DEPLOYABLE CLEANING ASSEMBLY
IL214840A0 (en) Humanised antibodies with anti-tumour activity
GB201100663D0 (en) Convertable having a roof arrangement
NO20101649A1 (no) Paravane med en syvende bridleline
HK1147895A2 (en) A convenient close-stool with heater
GB201017166D0 (en) Fuel metering control
HRP20180498T1 (hr) Blatobranska naprava s držačem za kabel
PL2363542T3 (pl) Zespół sterujący
PL2607565T3 (pl) Oparcie grzbietu dachu kedarowego oraz instalacja oparcia dachu kedarowego
GB201000274D0 (en) Fuel control arrangement
FR2965369B1 (fr) Videoendoscope a commandes tactiles configurables
FR2955080B1 (fr) Tricycle a direction parentale
DK2468965T3 (da) Multifunktionsfastgørelseselement med en ledningsvinkel
EP2539526A4 (en) WINDOW COVER WITH IMPROVED CONTROL MECHANISMS
FR2958094B1 (fr) Convertisseur alternatif / continu a isolement galvanique
FR2965898B1 (fr) Chauffe-eau parallelepipedique a cloisons longitudinales trouees
TWM388408U (en) A mould with flat thimble